In a written reply, the Union Health Minister Mansukh Mandaviya says vaccination protects against severe manifestations of the disease and improves herd immunity, and thus potentially mitigates the impact COVID-19 could have with any resurgence. any in the future.
The vaccines currently used for vaccination offer significant protection against infection, in addition to reducing disease severity, hospitalizations and deaths, he said.
Following the warnings of health experts and authorities about the possible emergence of a third wave of the coronavirus in the form of its variant, which is likely to affect children, Mandaviya explained that there is no There is no scientific evidence in India or globally that children disproportionately contract the disease. infected with COVID-19, including its Delta variant.
Many waves have been noticed around the world, he said.
“The (third) wave can be caused by mutations in the virus or by pre-existing susceptible populations, which also depend on different pharmaceutical and non-pharmaceutical interventions to respond to this,” he said. pandemic management,” he said.
According to the World Health Organization, the Delta variant of SARS-CoV-2 shows higher transmissibility than other mutant variants of interest (VOC) identified to date.
“However, there is no scientific evidence from India or globally that children are disproportionately infected with COVID-19, including the Delta variant. Children, if infected, usually do not. symptoms or showing mild symptoms and not being severely ill,” Mandaviya stated.
However, the Department of Health has issued specific guidelines and recommended states to upgrade health infrastructure related to pediatric case management, he said.
Regarding preparedness to combat the intensity of the third wave, he said the Department monitors the trajectory of Covid according to details provided by the states.
The public health approach and clinical management protocol for the Delta variant remain the same, he said.
Health is the subject of the state, the Center provides the necessary technical assistance to the states and has assisted them in the direction of strengthening the health infrastructure to ensure adequate beds, medicines, medical oxygen and other essentials. other consumables to support appropriate clinical care for COVID-19 patients, the minister said.
Due to the coordinated actions of the Center and the state government, isolation bed capacity and ICU bed capacity, which were 10,180 and 2,168 before the first lockdown (on March 23, 2020) are being increased and are now at 18,21,845 isolation beds and 1,22,035 ICU beds, on July 20, he said.
States, union territories and central government organizations have been allocated 56,218 ventilators with 48,446 already supplied, as of July 19, he said.
Regarding medical oxygen supplies, he said liquid medical oxygen (LMO) production rose to a high of 9,690 tons on May 13.
This is done by increasing output at steel mills and other LMO plants, the minister said.
He said a system for real-time monitoring of oxygen production in steel mills and distribution to states and UTs has been put in place and restrictions are in place on industrial use.
He said a dynamic and transparent framework for oxygen allocation in consultation with states and UTs and all stakeholders has been prepared.
The Oxygen Demand Synthesis System and the Oxygen Digital Tracking System have been developed to identify demand from medical facilities and track transportation, he said.
The minister said 1,02,400 oxygen cylinders were purchased last April and May and distributed to the states. Additional orders for 1,27,000 cylinders were placed on April 21 – 54,000 jumbo cylinders (class D) and 73,000 conventional cylinders (class B).
Deliveries have commenced and 24,207 – 24,511 Class B cylinders and 8,893 Class D cylinders were delivered on July 7. In addition, approximately 4,962 Class B cylinders and 1,895 Class D cylinders are being shipped, Mr. speak.
To generate oxygen at the medical facility level, PSA plants are being installed, especially in remote areas, making it possible for hospitals to self-supply oxygen and thus, reducing the burden on the supply grid. medical oxygen supply across the country, the minister said.
To improve Vaccine Accessibility, manufacturers are being provided with the necessary ownership to ramp up production, and newer vaccines are also being planned for inclusion in COVID-19 vaccination operations, he said. will further improve availability, he said.
On whether the government is preparing a plan to use the nasal vaccine or use an imported vaccine for children, the Minister said that the Central Drug Standards Control Organization (CDSCO) has licensed it. conducting a phase I clinical trial of a vaccine for the nasal virus COVID-19. (BBV154) – in the age group 18 and up – arrived at Bharat Biotech on 12 February.
So far, as it relates to childhood vaccines, CDSCO granted permission on May 12 to conduct clinical trials of vaccines in children – phase II/III clinical trials – for Bharat Biotech in the age group of two to 18 years for the whole inactivated SARS-CoV-2 vaccine virion; and on January 4, authorize — a phase III clinical trial – for Cadila Healthcare Ltd in the age group 12 years and older for a DNA-based vaccine, he said.
The results of clinical trials are dependent on data obtained from the trial for the purpose of approval for placing on the domestic market. In addition, CDSCO has not authorized clinical trials of any imported COVID-19 vaccines on domestic children, he said.
https://economictimes.indiatimes.com/news/india/3rd-covid-wave-may-occur-either-due-to-mutations-in-virus-or-pool-of-susceptible-population-govt/articleshow/84682684.cms | 3rd Covid wave may occur either due to mutations in virus or pool of susceptible population: Govt